Hemostatic system state and cytokine profile in patients with metabolic syndrome

Abstract

Aim. Examine the hemostasis state and cytokine profile in patients with metabolic syndrome.

Methods. The study included 71 patients aged 20 to 44 years. Patients were allocated to four groups matched on age: the first group - females with the metabolic syndrome (n=15), the second - healthy females (control group, n=20), the third - males with the metabolic syndrome (n=19), the fourth group - healthy males (control group, n=17). Laboratory parameters of lipid, carbohydrate metabolism, hemostatic parameters, the levels of cytokines were measured in peripheral blood.

Results. Changes in plasma, fibrinolytic and anticoagulant links were revealed in metabolic syndrome (increased concentration of fibrinogen, soluble fibrin monomer complex, D-dimer - in patients of both gender, increased level of tissue factor pathway inhibitor and plasminogen activator inhibitor type 1 - in females). Metabolic syndrome was associated with an increased concentration of interleukin-6 (males and females), interleukin-10 (females) and decreased level of interleukin-8 (males) in peripheral blood. In females, the interrelation between fibrinolytic system activity and pro-inflammatory cytokines serum levels was revealed. In males with metabolic syndrome, a correlation of interleukin-6 pro-inflammatory cytokine level and D-dimer, interferon γ, insulin and insulin resistance index (HOMA) levels was discovered. The level of anti-inflammatory cytokine interleukin-10 correlated with serum triglycerides level.

Conclusion. Metabolic syndrome in patients of younger age is accompanied by changes in plasma fibrinolytic links of hemostasis, regardless of gender. In patients with metabolic syndrome, there are no gender differences in levels of peripheral blood cytokines inherent in healthy people.

Keywords

metabolic syndrome / hemostasis / cytokines / gender differences

References

[1] Ведунова М.В., Конторщикова К.Н., Добротина Н.А. Уровень эндогенной интоксикации при метаболическом синдроме // Вестн. ННГУ им. Лобачевского. Сер. Биология. - 2008. - №2. - С. 87-90.

[2] Куршаков А.А., Сайфутдинов Р.Г., Анчикова Л.И. и др. Инсулинорезистентность и эндотелиальная дисфункция при метаболическом синдроме // Казанский мед. ж. - 2011. - Т. 92, №2. - С. 173-176.

[3] Сумеркина В.А., Чулков Вл.С. Гендерные особенности системы свёртывания крови, углеводного и липидного обмена при метаболическом синдроме и изолированном абдоминальном ожирении // Изв. Самарского НЦ РАН. - 2014. - Т. 16, №5. - С. 1422-1426.

[4] Трошина И.А., Гагина Т.А., Петров И.М., Медведева И.В. Метаболический синдром как проявление взаимосвязи нервной, эндокринной и иммунной систем // Вестн. НГУ. Сер. Биол., клин. мед. - 2006. - Т. 4, №3. - С. 92-101.

[5] Шишова А.С., Горяйнов И.И., Лукашов А.А. Влияние терапии на показатели активности иммунного воспаления, нарушений упруго-эластических свойств сосудистого русла у больных артериальной гипертензией с метаболическим синдромом // Науч. вед. Белгородского гос. ун-та. Сер. Мед. фарм. - 2012. - Т. 18, №10. - С. 67-72.

[6] Akanji A.O., Smith R.J. The insulin-like growth factor system, metabolic syndrome, and cardiovascular disease risk // Met. Synd. Rel. Disord. - 2012. - Vol. 10, N 1. - Р. 3-13. http://dx.doi.org/10.1089/met.2011.0083

[7] Chiang D.J., Pritchard M.T., Nagy L.E. Obesity, diabetes mellitus, and liver fibrosis // AJP - Gastrointest. Liver Physiol. - 2011. - Vol. 300, N 5. - Р. 697-702. http://dx.doi.org/10.1152/ajpgi.00426.2010

[8] De la Fuente М., de Castro N.M. Obesity as a model of premature immunosenescence // Curr. Immunol. Rev. - 2012. - Vol. 8, N 1. - Р. 63-75. http://dx.doi.org/10.2174/157339512798991290

[9] Godsland I.F., Crook D., Proudler A.J., Stevenson J.C. Hemostatic risk factors and insulin sensitivity, regional body fat distribution, and the metabolic syndrome // J. Clin. Endocrinol. Metab. - 2005. - Vol. 90. - P. 190-197. http://dx.doi.org/10.1210/jc.2004-1292

[10] Horigome H., Katayama Y., Yoshinaga M. et al. Significant associations among hemostatic parameters, adipokines, and components of the metabolic syndrome in Japanese preschool children // Clin. Appl. Thromb. Hemost. - 2012. - Vol. 18, N 2. - Р. 189-194. http://dx.doi.org/10.1177/1076029611418962

[11] Meas T., Deghmoun S., Chevenne D. et al. Plasminogen activator inhibitor type-1 is an independent marker of metabolic disorders in young adults born small for gestational age // J. Thromb. Haemost. - 2010. - Vol. 8. - P. 2608-2613. http://dx.doi.org/10.1111/j.1538-7836.2010.04037.x

[12] Palomo I., Alarcon M., Moore-Carrasco R., Argiles J.M. Hemostasis alterations in metabolic syndrome (Review) // Int. J. Mol. Medicine. - 2006. - Vol. 18. - P. 969-974. http://dx.doi.org/10.3892/ijmm.18.5.969

[13] Rudnicka A.R., Rumley A.,Whincup P.H. et al. Sex differences in the relationship between inflammatory and hemostatic biomarkers and metabolic syndrome: British 1958 Birth Cohort // J. Thromb. Haemost. - 2011. - Vol. 9. - P. 2337-2344. http://dx.doi.org/10.1111/j.1538-7836.2011.04517.x

[14] Tahergorabi Z., Khazaei M. The relationship between inflammatory markers, angiogenesis, and obesity // ARYA Atheroscler. - 2013. - Vol. 9, N 4. - Р. 247-253.

[15] Xu A., Wang Y., Xu J.Y. et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome // Clin. Chem. - 2006. - Vol. 52, N 3. - Р. 405-413. http://dx.doi.org/10.1373/clinchem.2005.062463

RIGHTS & PERMISSIONS

Sumerkina V.A., Chulkov V.S., Chulkov V.S., Ozhigina E.V.